00:09 , May 8, 2019 |  BC Extra  |  Company News

Regeneron falls after reporting EPS below the Street and disclosing patient deaths

Regeneron lost $2.4 billion in market cap Tuesday after reporting 1Q19 EPS well below consensus and disclosing two patient deaths in a Phase I trial evaluating its bispecific mAb targeting CD20 and CD3, REGN1979, in...
15:04 , May 7, 2019 |  BC Extra  |  Clinical News

Viela reports detailed Phase II/III data for rare CNS disorder therapy

Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on...
00:06 , May 3, 2019 |  BC Extra  |  Company News

O’Day touts cell therapies as Gilead beats on EPS

On his first earnings call as CEO of Gilead, Daniel O'Day said more M&A and deals by the bellwether within cell therapy are "fundamental and essential" as the company reported 1Q19 earnings Thursday that beat...
22:16 , Apr 24, 2019 |  BC Extra  |  Clinical News

Gracell reports more potent CD19 CAR T using single-day manufacturing platform

Gracell said its platform was able to manufacture in a single day a CD19-targeting CAR T cell therapy shown to be 20-40 times more potent than conventionally manufactured CAR T therapies in a first-in-human Phase...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
22:53 , Mar 27, 2019 |  BC Extra  |  Financial News

With $126M IPO, Precision aims to bring allogeneic CAR T to clinic this half

Precision raised $126.4 million Wednesday in a NASDAQ IPO that values the gene editing company at about $784.5 million. Precision BioSciences Inc. (NASDAQ:DTIL) sold 7.9 million shares at $16, the midpoint of its proposed range....
20:17 , Mar 25, 2019 |  BC Innovations  |  Distillery Therapeutics

CD19 CAR T cells for lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Mouse studies suggest CD19-targeted CAR T cells could help treat lupus. In two mouse models of lupus, retro-orbital injection of CD19-targeting CAR T cells decreased the number of CD19-positive...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ. Precision plans to start...
22:34 , Mar 7, 2019 |  BC Extra  |  Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...